Arrowhead Pharmaceuticals (ARWR) Upgraded at BidaskClub

Arrowhead Pharmaceuticals (NASDAQ:ARWR) was upgraded by BidaskClub from a “buy” rating to a “strong-buy” rating in a note issued to investors on Thursday, January 18th.

A number of other research analysts have also recently commented on the company. B. Riley began coverage on Arrowhead Pharmaceuticals in a research note on Friday, January 5th. They issued a “neutral” rating and a $3.00 target price for the company. Cantor Fitzgerald set a $2.00 target price on Arrowhead Pharmaceuticals and gave the company a “hold” rating in a research note on Tuesday, December 12th. ValuEngine upgraded Arrowhead Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Thursday, November 30th. Finally, Piper Jaffray Companies raised Arrowhead Pharmaceuticals from a “neutral” rating to an “overweight” rating and set a $5.50 target price for the company in a report on Monday, November 27th. Five investment analysts have rated the stock with a hold rating, two have given a buy rating and one has given a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and an average price target of $3.13.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) traded down $0.07 on Thursday, hitting $5.59. The stock had a trading volume of 1,138,724 shares, compared to its average volume of 2,270,000. The stock has a market cap of $418.29, a PE ratio of -11.89 and a beta of 2.52. The company has a current ratio of 3.63, a quick ratio of 3.63 and a debt-to-equity ratio of 0.03. Arrowhead Pharmaceuticals has a 52 week low of $1.42 and a 52 week high of $6.75.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last released its earnings results on Tuesday, December 12th. The biotechnology company reported ($0.14) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.12) by ($0.02). The firm had revenue of $8.71 million during the quarter, compared to analysts’ expectations of $7.32 million. Arrowhead Pharmaceuticals had a negative net margin of 109.46% and a negative return on equity of 38.10%. sell-side analysts predict that Arrowhead Pharmaceuticals will post -0.74 EPS for the current fiscal year.

In related news, COO Bruce D. Given sold 20,000 shares of Arrowhead Pharmaceuticals stock in a transaction on Monday, January 1st. The stock was sold at an average price of $3.69, for a total transaction of $73,800.00. Following the transaction, the chief operating officer now directly owns 948,356 shares in the company, valued at $3,499,433.64. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 4.60% of the company’s stock.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Schwab Charles Investment Management Inc. lifted its position in Arrowhead Pharmaceuticals by 8.8% during the fourth quarter. Schwab Charles Investment Management Inc. now owns 186,381 shares of the biotechnology company’s stock valued at $686,000 after purchasing an additional 15,132 shares in the last quarter. Dimensional Fund Advisors LP lifted its position in Arrowhead Pharmaceuticals by 252.2% during the third quarter. Dimensional Fund Advisors LP now owns 44,358 shares of the biotechnology company’s stock valued at $192,000 after purchasing an additional 31,765 shares in the last quarter. Wells Fargo & Company MN lifted its position in Arrowhead Pharmaceuticals by 237.3% during the fourth quarter. Wells Fargo & Company MN now owns 69,997 shares of the biotechnology company’s stock valued at $257,000 after purchasing an additional 49,246 shares in the last quarter. Virtu KCG Holdings LLC lifted its position in Arrowhead Pharmaceuticals by 115.6% during the second quarter. Virtu KCG Holdings LLC now owns 99,267 shares of the biotechnology company’s stock valued at $161,000 after purchasing an additional 53,215 shares in the last quarter. Finally, Acadian Asset Management LLC lifted its position in Arrowhead Pharmaceuticals by 1,177.7% during the fourth quarter. Acadian Asset Management LLC now owns 71,664 shares of the biotechnology company’s stock valued at $264,000 after purchasing an additional 66,055 shares in the last quarter. Institutional investors own 21.03% of the company’s stock.

WARNING: This story was first published by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are viewing this story on another website, it was copied illegally and reposted in violation of US & international trademark and copyright legislation. The original version of this story can be accessed at https://ledgergazette.com/2018/02/12/arrowhead-pharmaceuticals-arwr-rating-increased-to-strong-buy-at-bidaskclub.html.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc, formerly Arrowhead Research Corporation, develops medicines that treat intractable diseases by silencing the genes that cause them. Using a portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, the Company’s therapies trigger the RNA interference mechanism to induce knockdown of target genes.

Analyst Recommendations for Arrowhead Pharmaceuticals (NASDAQ:ARWR)

Receive News & Ratings for Arrowhead Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply